We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+47.12%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$367M
AUM Growth
-$744K
Cap. Flow
-$75M
Cap. Flow %
-20.41%
Top 10 Hldgs %
48.04%
Holding
60
New
17
Increased
14
Reduced
15
Closed
9

Top Buys

Rank Stock Value
1
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$9.03M
2
REPL icon
Replimune Group
REPL
+$8.65M
3
VTGN icon
VistaGen Therapeutics
VTGN
+$6.38M
4
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$5.73M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.66M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$43.5M
2
KURA icon
Kura Oncology
KURA
+$11.8M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$10.2M
4
CYTK icon
Cytokinetics
CYTK
+$7.74M
5
LSACU
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
+$7.62M

Sector Composition

Rank Sector Weight
1 Healthcare 89.24%
2 Financials 4.13%
3 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
26
Stoke Therapeutics
STOK
$2.06B
$5.73M 1.56%
+92,500
New +$4.24M
VSTM icon
27
Verastem
VSTM
$519M
$5.11M 1.39%
200,000
– –
OBIO icon
28
Orchestra BioMed
OBIO
$249M
$5.03M 1.37%
392,500
– –
AVDL
29
DELISTED
Avadel Pharmaceuticals
AVDL
$4.71M 1.28%
705,218
– –
CRIS icon
30
Curis
CRIS
$8.59M
$4.34M 1.18%
+1,325
New +$1.59M
BHVN
31
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.29M 1.17%
+50,000
New +$4.24M
PRAX icon
32
Praxis Precision Medicines
PRAX
$10.3B
$4.16M 1.13%
+5,043
New +$2.94M
RAPT
33
DELISTED
RAPT Therapeutics
RAPT
$4.14M 1.13%
26,200
-3,800
-13% -$826K
RLMD icon
34
Relmada Therapeutics
RLMD
$564M
$3.85M 1.05%
120,000
-157,000
-57% -$5.39M
CCCC icon
35
C4 Therapeutics
CCCC
$402M
$3.64M 0.99%
+110,000
New +$3.19M
MDGL icon
36
Madrigal Pharmaceuticals
MDGL
$11.8B
$3.61M 0.98%
+32,500
New +$3.97M
CLSD
37
DELISTED
Clearside Biomedical
CLSD
$3.42M 0.93%
83,333
+42,333
+103% +$1.1M
CBAY
38
DELISTED
Cymabay Therapeutics
CBAY
$1.89M 0.52%
330,000
-435,000
-57% -$3.29M
ONCR
39
DELISTED
Oncorus, Inc.
ONCR
$1.73M 0.47%
+53,500
New +$1.24M
ALDX icon
40
Aldeyra Therapeutics
ALDX
$95.9M
$1.32M 0.36%
192,500
-1,454,200
-88% -$10.2M
XENE icon
41
Xenon Pharmaceuticals
XENE
$6.24B
$1.23M 0.33%
80,000
-220,000
-73% -$2.57M
BGMS
42
Bio Green Med Solution Inc
BGMS
$5.35M
$1.17M 0.32%
+42
New +$642K
RCKT icon
43
Rocket Pharmaceuticals
RCKT
$387M
$1.1M 0.3%
+20,000
New +$729K
PMVP icon
44
PMV Pharmaceuticals
PMVP
$62.9M
$923K 0.25%
+15,000
New +$588K
WVE icon
45
Wave Life Sciences
WVE
$1.19B
$846K 0.23%
107,500
– –
FDMT icon
46
4D Molecular Therapeutics
FDMT
$552M
$829K 0.23%
+20,000
New +$826K
ANNX icon
47
Annexon
ANNX
$918M
$626K 0.17%
25,000
-85,000
-77% -$2.19M
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$508K 0.14%
5,000
-8,500
-63% -$788K
AXSM icon
49
Axsome Therapeutics
AXSM
$10.8B
$489K 0.13%
6,000
-16,500
-73% -$1.23M
PANA.WS
50
DELISTED
Panacea Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one share of Class
PANA.WS
$299K 0.08%
+93,332
New +$214K
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Acuta Capital Partners held 60 positions worth $367M, down 0.2% from $368M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Acuta Capital Partners withdrew a net $75M in Q4 2020, closing 9 positions and reducing 15 holdings. Its most notable exit was Immunomedics Inc, an estimated $43.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 74% a quarter earlier, followed by Financials and Industrials.

Against the trend, Acuta Capital Partners opened a new position in BCLS Acquisition Corp. Class A Ordinary Shares worth $9.38M.

  • Acuta Capital Partners's largest Q4 2020 buy was BCLS Acquisition Corp. Class A Ordinary Shares: 842,500 shares worth $9.38M.
  • Acuta Capital Partners added most to Syndax Pharmaceuticals in Q4 2020, an estimated $4.66M increase.
  • Acuta Capital Partners's biggest Q4 2020 reduction was Kura Oncology, cutting an estimated $11.8M.
  • Acuta Capital Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $43.5M.
  • Acuta Capital Partners's ten largest holdings make up 48% of its $367M portfolio in Q4 2020.
  • Acuta Capital Partners opened 17 new positions and closed 9 in Q4 2020.
  • Acuta Capital Partners's portfolio value fell 0.2% quarter-over-quarter to $367M.

Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.